HONG KONG - U.S. and China-based Terns Pharmaceuticals Inc. closed an $87 million series C financing round that will pave the way for the company’s pipeline of candidates to treat nonalcoholic steatohepatitis (NASH).
LONDON – Theolytics Ltd. raised $6.8 million in a series A round to further develop its platform technology and advance the lead oncolytic virus program toward the clinic.
Lexeo Therapeutics Inc., a New York-based startup initially advancing clinical and near-clinical stage candidates for Friedreich’s ataxia, CLN2 and Alzheimer's diseases, has raised an $85 million series A financing round led by Longitude Capital and Omega Funds. Founded by gene therapy development veteran Ronald Crystal, the company is led by CEO Nolan Townsend, the former head of Pfizer Inc.'s rare disease efforts in North America.
In less than a year, Scorpion Therapeutics Inc. has raised about $270 million and just closed on an oversubscribed series B financing that climbed to $162 million. The new financing quickly follows the Boston-based company’s founding at the end of the first quarter of 2020 and the closure of a $108 million series A financing in October.
Abcuro Inc. raised $42 million in a series A-1 round to progress preclinical programs in autoimmune disease and cancer involving a largely overlooked immune checkpoint receptor, killer cell lectin-like receptor G1 (KLRG1).
Immuneering Corp., a bioinformatics specialist that has for years helped big companies like Teva Pharmaceutical Ltd. and Bristol Myers Squibb Co. better understand their own medicines, has landed $62 million in an oversubscribed series B financing that will help it leverage lessons learned in that journey to build out its own pipeline, starting with IMM-1-104, a dual inhibitor of MEK and a related target.
Iconovir Bio Inc., of San Diego, raised $77 million in a series A financing to develop differentiated oncolytic virus candidates the company said it believes could potentially be I.V.-administered, tumor-selective and could broadly infect tumor cells.
RSS
